🇺🇸 FDA
Patent

US 9868725

Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimer's disease

granted A61KA61K31/045A61K31/13

Quick answer

US patent 9868725 (Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimer's disease) held by Takeda Pharmaceutical Company Limited expires Mon Jan 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Jan 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/045, A61K31/13, A61K31/325, A61K31/4035